XERIS BIOPHARMA HOLDINGS INC (XERS)
US98422E1038 - Common Stock
Overall XERS gets a fundamental rating of 2 out of 10. We evaluated XERS against 198 industry peers in the Pharmaceuticals industry. XERS has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, XERS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
XERS had negative earnings in the past year.
XERS had a negative operating cash flow in the past year.
In the past 5 years XERS always reported negative net income.
XERS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
XERS's Return On Assets of -19.30% is fine compared to the rest of the industry. XERS outperforms 62.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.3% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-29.03%
ROA(5y)-51.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 82.52%, XERS belongs to the top of the industry, outperforming 85.64% of the companies in the same industry.
XERS's Gross Margin has declined in the last couple of years.
XERS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.52% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.89%
GM growth 5Y-2.98%
2. Health
2.1 Basic Checks
XERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, XERS has more shares outstanding
Compared to 5 years ago, XERS has more shares outstanding
The debt/assets ratio for XERS is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -1.94, we must say that XERS is in the distress zone and has some risk of bankruptcy.
XERS has a Altman-Z score (-1.94) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.94 |
ROIC/WACCN/A
WACC11.09%
2.3 Liquidity
A Current Ratio of 1.64 indicates that XERS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.64, XERS is not doing good in the industry: 73.33% of the companies in the same industry are doing better.
XERS has a Quick Ratio of 1.23. This is a normal value and indicates that XERS is financially healthy and should not expect problems in meeting its short term obligations.
XERS's Quick ratio of 1.23 is on the low side compared to the rest of the industry. XERS is outperformed by 74.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
XERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 35.71%, which is quite impressive.
XERS shows a strong growth in Revenue. In the last year, the Revenue has grown by 48.68%.
The Revenue has been growing by 130.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)35.71%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)48.68%
Revenue growth 3Y100.29%
Revenue growth 5Y130.85%
Revenue growth Q2Q33.95%
3.2 Future
XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.54% yearly.
The Revenue is expected to grow by 15.81% on average over the next years. This is quite good.
EPS Next Y12.73%
EPS Next 2Y22.53%
EPS Next 3Y29.06%
EPS Next 5Y30.54%
Revenue Next Year13.41%
Revenue Next 2Y16.13%
Revenue Next 3Y16.74%
Revenue Next 5Y15.81%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XERS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XERS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
XERS's earnings are expected to grow with 29.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.53%
EPS Next 3Y29.06%
5. Dividend
5.1 Amount
No dividends for XERS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
XERIS BIOPHARMA HOLDINGS INC
NASDAQ:XERS (4/29/2024, 9:06:06 AM)
1.73
-0.02 (-1.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap242.98M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -19.3% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 82.52% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)35.71%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y12.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)48.68%
Revenue growth 3Y100.29%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y